D2B3 Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $480K

  • Investors
  • 6

D2B3 General Information

Description

Operator of a pre-clinical biotechnology platform intended to advance drug delivery to the brain and central nervous system. The company offers proprietary technology that transiently and specifically opens the blood-brain barrier, enabling the targeting of CNS diseases with high efficacy, and providing a versatile, plug-and-play approach for most drugs and therapeutic classes.

Contact Information

Website
www.d2b3.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Vertical(s)
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States

D2B3 Timeline

20252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

D2B3 Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator 07-Apr-2025 $480K Completed Pre-Clinical Trials
5. Early Stage VC 01-Jan-2025 Completed Pre-Clinical Trials
4. Accelerator/Incubator 24-Sep-2024 Completed Pre-Clinical Trials
3. Accelerator/Incubator 26-Jul-2024 Completed Product Development
2. Accelerator/Incubator 01-Jun-2024 $400K Completed Product Development
1. Seed Round 01-Jan-2022 $400K $400K Completed Product Development
To view D2B3’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

D2B3 Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a pre-clinical biotechnology platform intended to advance drug delivery to the brain and central nervous sys
Biotechnology
New Haven, CT
3 As of 2026

Dublin, Ireland
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

D2B3 Competitors (2)

One of D2B3’s 2 competitors is Aerska, a Venture Capital-Backed company based in Dublin, Ireland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aerska Venture Capital-Backed Dublin, Ireland
Denali Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 2 of 2 competitors. Get the full list »

D2B3 Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

D2B3 Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Creative Destruction Lab Accelerator/Incubator
Connecticut Innovations Venture Capital Minority
Mission BioCapital Venture Capital Minority
MassBio Accelerator/Incubator
IndieBio Accelerator/Incubator
You’re viewing 5 of 6 investors. Get the full list »

D2B3 FAQs

  • When was D2B3 founded?

    D2B3 was founded in 2024.

  • Where is D2B3 headquartered?

    D2B3 is headquartered in New Haven, CT.

  • What is the size of D2B3?

    D2B3 has 3 total employees.

  • What industry is D2B3 in?

    D2B3’s primary industry is Biotechnology.

  • Is D2B3 a private or public company?

    D2B3 is a Private company.

  • What is D2B3’s current revenue?

    The current revenue for D2B3 is .

  • How much funding has D2B3 raised over time?

    D2B3 has raised $980K.

  • Who are D2B3’s investors?

    Creative Destruction Lab, Connecticut Innovations, Mission BioCapital, MassBio, and IndieBio are 5 of 6 investors who have invested in D2B3.

  • Who are D2B3’s competitors?

    Aerska and Denali Therapeutics are competitors of D2B3.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process